N/A N=54 Treatment

Proton Radiation for Chordomas and Chondrosarcomas

Chordomas · Chondrosarcomas

Bottom Line

View on ClinicalTrials.gov: NCT01449149 ↗

Enrolled (actual)

Serious AEs

27.8%

Results posted

Dec 2025

Primary outcome: Primary: Feasibility of Proton RT for Chordomas and Chondrosarcomas — 3.7; 1.9 percentage of patients did not meet this

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Proton Therapy (Radiation)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Abramson Cancer Center at Penn Medicine
Primary completion: Jul 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Feasibility of Proton RT for Chordomas and Chondrosarcomas	3.7; 1.9	—
SECONDARY Acute Toxicities	37; 28; 14; 9; 9; 7	—
SECONDARY Late Toxicities	17; 8; 4; 1; 2; 1	—

Summary

The objectives of this study are 1) To evaluate the feasibility and acute side effects of proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and long term side effects of proton beam radiation for treatment of chordomas and chondrosarcomas.

Eligibility Criteria

Inclusion Criteria

Histologically confirmed diagnosis of chordoma or chondrosarcoma.
Patients must have no evidence of metastatic disease based on routine imaging (CT or MRI of the chest/abdomen/pelvis, bone scan, etc.)
Patients must have an ECOG score equal to or less than 2.
Age ≥ 18 years.
Patients must be able to provide informed consent.
Adequate bone marrow function: WBC ≥ 4000/mm3, platelets ≥ 100, 000mm3
Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive , IUD, condoms or other barrier methods etc.) Hysterectomy or menopause must be clinically documented.
Tumors arising in the skull and spine.

Exclusion Criteria

Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
Patients with the following histologies are excluded: melanoma , other soft tissue or bony sarcomas, giant cell tumor aneurismal bone cyst or metastatic lesions from other histologies.
Pregnant women.
Actively being treated on any other therapeutic research study.
Tumors arising outside of the CNS.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01449149). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.